Glimepirid Hexal

Glimepirid Hexal is a prescription oral medication that contains the active ingredient glimepiride, a sulfonylurea class antidiabetic agent. It is supplied as tablets (strength not specified) and is intended for use in the European Union market. The product works by stimulating insulin release from pancreatic beta cells, helping to lower blood glucose levels in patients with type 2 diabetes mellitus.

Glimepirid Hexal is indicated for the management of type 2 diabetes mellitus as part of a comprehensive treatment plan that includes diet and exercise. It may be used when monotherapy with other oral agents does not achieve glycemic targets, and it can be combined with other antidiabetic drugs.

- Adjunct to diet and exercise for type 2 diabetes. - Used when other oral agents are insufficient to control blood glucose. - Can be combined with metformin or other non‑insulin therapies. - Suitable for patients with residual pancreatic beta‑cell function. - May be considered in adults who require additional glycemic control.

Glimepirid Hexal may cause a range of side effects, some of which are more frequently observed while others are less common but potentially serious.

Common: - Mild hypoglycemia, especially when meals are missed. - Weight gain due to increased insulin activity. - Nausea or gastrointestinal discomfort. - Headache or dizziness. - Fatigue or weakness.

Serious: - Severe hypoglycemia requiring medical attention. - Allergic reactions such as rash, pruritus, or angioedema. - Blood dyscrasias including leukopenia or thrombocytopenia. - Hepatotoxicity manifested by jaundice or elevated liver enzymes. - Cardiovascular events in patients with pre‑existing heart disease.

Before starting Glimepirid Hexal, several precautionary measures should be considered to ensure safe use.

- Assess renal and hepatic function; dose adjustments may be needed in impairment. - Use cautiously in elderly patients who may be more sensitive to hypoglycemia. - Pregnancy and lactation status are not well established; discuss risks with a healthcare provider. - Monitor blood glucose regularly to detect hypoglycemia early. - Avoid overdose; educate patients on recognizing symptoms of low blood sugar. - Adjust dose when initiating or discontinuing concomitant medications that affect glucose metabolism. - Evaluate cardiovascular status, as sulfonylureas may influence heart disease risk.

Glimepirid Hexal can interact with a variety of medicines, altering its effectiveness or increasing the risk of adverse events.

Avoid: - Other sulfonylureas or meglitinides, which can cause additive hypoglycemia. - Strong CYP2C9 inhibitors (e.g., fluconazole, amiodarone) that raise glimepiride plasma levels. - MAO inhibitors, which may potentiate hypoglycemic effects.

Use with caution: - Beta‑blockers, which may mask hypoglycemia symptoms. - Thiazide diuretics, which can affect glucose control. - ACE inhibitors or ARBs, as they may influence renal function. - Non‑steroidal anti‑inflammatory drugs (NSAIDs), which can affect renal clearance. - Alcohol, which can potentiate hypoglycemia, especially when consumed with meals.